[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612586":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":91,"collaborators":93,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":10,"enrollmentInfo":106,"targetDuration":109,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":118,"whyStopped":10,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group",null,"Prostatic Artery Embolization",[13],"Device: Liquid embolic agent",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Liquid embolic agent","Prostatic Artery Embolization using a non-adhesive liquid embolic agent composed of an EVOH (ethylene-vinyl alcohol) copolymer dissolved in DMSO (dimethyl sulfoxide), with micronized tantalum powder suspended within it",[9],[21],"Squid Peri",[23],{"name":24,"affiliation":5,"role":25},"Marc SAPOVAL","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Touria EL AAMRI, Project manager","CONTACT","+33 (0)1 40 27 18 48","touria.el-aamri@aphp.fr",[33,50,64,77],{"facility":34,"status":10,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Hôpital Timone (Radiologie adultes et neuroradiologie)","Marseille","13385","France","FR",{"type":40,"coordinates":41},"Point",[42,43],5.38107,43.29695,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":48,"phoneExt":10,"email":49},"Vincent VIDAL","+33 (0) 4 13 42 90 60","vincent.vidal@ap-hm.fr",{"facility":51,"status":10,"city":52,"state":10,"zip":53,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Hôpital Arnaud de Villeneuve (Service Imagerie diagnostique et interventionnelle)","Montpellier","34295",{"type":40,"coordinates":55},[56,57],3.87635,43.61093,{"lat":57,"lon":56},[60],{"name":61,"role":29,"phone":62,"phoneExt":10,"email":63},"Hélène KOVACSIK","+33 (0) 4 67 33 60 00","h-vernhet@chu-montpellier.fr",{"facility":65,"status":10,"city":66,"state":10,"zip":67,"country":37,"countryCode":38,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Hôpital Européen Georges Pompidou - AP-HP (Radiologie Interventionnelle vasculaire et oncologique)","Paris","75015",{"type":40,"coordinates":69},[70,71],2.3488,48.85341,{"lat":71,"lon":70},[74],{"name":24,"role":29,"phone":75,"phoneExt":10,"email":76},"+33 (0) 1 56 09 37 40","marc.sapoval2@aphp.fr",{"facility":78,"status":10,"city":79,"state":10,"zip":80,"country":37,"countryCode":38,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Institut Cardiovasculaire de Strasbourg (ICS) - Clinique Rhena (Radiologie interventionnelle vasculaire et oncologique)","Strasbourg","67000",{"type":40,"coordinates":82},[83,84],7.74553,48.58392,{"lat":84,"lon":83},[87],{"name":88,"role":29,"phone":89,"phoneExt":10,"email":90},"Gilles GOYAULT","+33 (0) 3 90 67 39 91","g.goyault@ics.clinique-rhena.fr",{"type":92,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[94],{"name":95,"class":96},"Balt International","INDUSTRY","100612586","efficacy-of-prostatic-arteries-embolization-using-squidperi-100612586",false,"NCT07255508","Efficacy of Prostatic Arteries Embolization Using SQUIDPERI","SQUID-PAE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patient scheduled for a PAE using SquidPERI as part of routine care\n* Patient informed who signed the informed consent form\n* French social security affiliation\n* Good understanding of the French language\n\nExclusion Criteria:\n\n* Patient unwilling or unlikely to comply with FU schedule\n* Known severe allergy to iodine\n* Known severe hepatic impairment\n* Vulnerable patient populations (such as patient under guardianship, curatorship, deprived of liberty)\n* Patient that already had a PAE\n* Patient on AME (state medical aid)\n* Participation in any interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable","MALE","18 Years",{"count":107,"type":108},100,"ESTIMATED","12 Months","OBSERVATIONAL","Prostatic Artery Embolization (PAE) is a recognized mini-invasive treatment of bothersome Lower Urinary Tract Symptoms (LUTS) related to Benign Prostatic Hyperplasia (BPH). Particle embolics are used almost exclusively for embolization, with wide variation in the type and size of particles showing similar performance and safety results. Even if its durability relies on multiple risk factors, LUTS recurrence-free survival probability decreases with years. It is demonstrated that recanalization of the native prostatic artery is found in 66% of patients experiencing LUTS recurrence. Artery recanalization after several months has been reported in embolization with microparticles. The investigators addressed this issue using the liquid embolic agent SQUIDPERI in a prospective cohort of patients undergoing rePAE and showed a good clinical success rate (76.7%) at 3 months. Since then, the investigators perform initial PAE using SQUIDPERI with good results.\n\nThe aim of SQUID-PAE study is to assess the efficacy of PAE using SQUIDPERI in an initial PAE setting in a multicenter prospective study.",[113],"Benign Prostate Hypertrophy(BPH)",[11,115,116,117],"PAE","SQUIDPERI","Liquid Embolic Agent","NOT_YET_RECRUITING","2025-11-20",{"date":121,"type":122},"2025-12-01","ACTUAL",{"date":124,"type":108},"2025-11",{"date":126,"type":108},"2027-11",{"name":5,"class":6},4]